All In Biotech

Drug Trial Radar · NCT02931539

Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

Last checked: Nov 19, 2026Latest source record: Nov 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 352 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

352

Actual

Start

Dec 22, 2016

Primary completion

Aug 17, 2020

Study completion Aug 17, 2020

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Oct 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV treatment.

Conditions

  • Cytomegalovirus (CMV)

Interventions

  • MaribavirDrug

    Maribavir 400 milligrams (mg) (2x200 mg tablets) will be administered twice daily for 8 weeks.

  • GanciclovirDrug

    Ganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.

  • ValganciclovirDrug

    Valganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.

  • FoscarnetDrug

    Foscarnet as per the investigator's prescribed dosing regimen will be administered for 8 weeks.

  • CidofovirDrug

    Cidofovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved Confirmed Clearance of Plasma Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) (CMV Viremia Clearance) at End of Week 8Time frame: Week 8

Locations

134 sites in 14 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Arizona

    Tucson, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • University of Southern California

    Los Angeles, California

  • UCLA Medical Center

    Los Angeles, California

  • UC Davis Medical Center

    Sacramento, California

  • Stanford University

    Stanford, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • AdventHealth

    Orlando, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • Feinberg School of Medicine Northwestern University

    Chicago, Illinois

  • Loyola University Medical Center

    Maywood, Illinois

  • University of Chicago Medical Center

    Maywood, Illinois

  • University of Kentucky

    Lexington, Kentucky

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • University of Maryland

    Baltimore, Maryland

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Womens Hospital

    Boston, Massachusetts

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • William Beaumont Hospital

    Royal Oak, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic - PPDS

    Rochester, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • New York Presbyterian Hospital - Weill-Cornell

    New York, New York

  • SUNY Upstate Medical Center

    Syracuse, New York

  • Duke University Medical Center

    Durham, North Carolina

  • The Christ Hospital

    Cincinnati, Ohio

  • University of Cincinnati

    Cincinnati, Ohio

  • Cincinnati Children's Hospital Medical Center - PIN

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina - PPDS

    Charleston, South Carolina

Showing 40 of 134 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.